Artificial Tears Study in Mild to Moderate Dry Eye Patients
NCT ID: NCT00607776
Last Updated: 2025-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
110 participants
INTERVENTIONAL
2007-01-31
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality
NCT00622037
Efficacy and Acceptability of Two Lubricant Eye Drops
NCT00756678
A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens
NCT01061268
Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
NCT00565669
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).
NCT00620893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Systane
Systane
Drops
2
Blink tears
(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400
Drops
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400
Drops
Systane
Drops
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* over 18
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Medical Optics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AMO, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Donnenfeld, M.D.
Role: PRINCIPAL_INVESTIGATOR
Ophthalmic Consultants of Long Island
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEGT-104-9582
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.